BSX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Boston Scientific Corp (BSX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown strong YoY financial growth, recent disappointing earnings, insider selling, and ongoing legal investigations raise concerns. Additionally, technical indicators suggest bearish trends, and the options data reflects a bearish sentiment. Despite some positive signals like Congress purchases and analysts maintaining a generally positive outlook, the stock's current situation does not align with the user's investment scenario.
The technical indicators for BSX are bearish. The MACD histogram is negative and contracting, the RSI is neutral at 20.176, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level of 74.157, with resistance levels at 90.625 and 95.712. This suggests limited upside potential in the near term.
Congress members have made significant purchases of BSX stock recently, indicating confidence in the company's long-term prospects.
Analysts maintain mostly positive ratings, with several firms viewing the recent selloff as an overreaction.
The company's financials for Q4 2025 showed strong YoY growth in revenue (15.90%), net income (18.94%), and EPS (18.42%).
Disappointing Q4 results, particularly in U.S. EP sales, which missed consensus by 6%.
Insider selling has increased significantly by 755.62% over the last month.
Legal investigations into potential securities law violations could negatively impact investor sentiment.
Bearish technical indicators and options data suggest limited short-term upside.
In Q4 2025, Boston Scientific reported strong YoY growth: Revenue increased by 15.90% to $5.286 billion, Net Income rose by 18.94% to $672 million, EPS grew by 18.42% to $0.45, and Gross Margin improved by 3.40% to 65.15%. However, the quarter was marked by a sequential flat performance in U.S. EP sales and missed consensus expectations.
Analysts have lowered price targets across the board following disappointing Q4 results, but most maintain Buy or Outperform ratings. Price targets now range from $94 to $115, down from prior estimates of $112 to $140. Analysts view the selloff as an overreaction but acknowledge the need for stability and upcoming clinical trial catalysts to regain investor confidence.
